As part of the acquisition, Creso will pay an US$250,000 exclusivity option payment and issue US$7.15 million shares at A$1.10 each, subject to regulatory approval and due diligence. According to Creso, the takeover positions it as the only ASX-listed medicinal cannabis company with direct exposure ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment